A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Primary To determine the safety, tolerability, and DLTs of INCB086550. Secondary To evaluate the PK of INCB086550 in participants with advanced solid tumors. To evaluate the pharmacodynamics of INCB086550 in participants with advanced solid tumors. To determine the preliminary efficacy of INCB086550 in participants with advanced solid tumors. Exploratory To explore biomarkers that predict pharmacologic activity. To evaluate biomarker correlations with clinical safety and early efficacy. To evaluate the efficacy of INCB086550 per iRECIST in participants with advanced solid tumors.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.